


# PRODUCT INFORMATION



**GSK2982772**

Item No. 29230

**CAS Registry No.:** 1622848-92-3  
**Formal Name:** 3-(phenylmethyl)-N-[(3S)-2,3,4,5-tetrahydro-5-methyl-4-oxo-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-5-carboxamide  
**MF:** C<sub>20</sub>H<sub>19</sub>N<sub>5</sub>O<sub>3</sub>  
**FW:** 377.4  
**Purity:** ≥98%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

GSK2982772 is supplied as a solid. A stock solution may be made by dissolving the GSK2982772 in the solvent of choice, which should be purged with an inert gas. GSK2982772 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of GSK2982772 in these solvents is approximately 5, 15, and 10 mg/ml, respectively.

GSK2982772 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, GSK2982772 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. GSK2982772 has a solubility of approximately 0.16 mg/ml in a 1:5 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

## Description

GSK2982772 is an inhibitor of receptor interacting serine/threonine kinase 1 (RIPK1; IC<sub>50</sub>s = 16 and 2,500 nM for the human and mouse enzymes, respectively).<sup>1</sup> It is greater than 10,000-fold selective for RIPK1 over a panel of 339 kinases at 10 μM. GSK2982772 inhibits necrotic cell death induced by a combination of TNF-α and the caspase inhibitor QVD-OPh in U937 human monocytic and L929 murine fibrosarcoma cells (IC<sub>50</sub>s = 6.3 and 1,300 nM, respectively). GSK2982772 (3-300 nM) decreases IL-1β and IL-6 levels in intestinal mucosa tissue isolated from patients with ulcerative colitis. It increases survival in a mouse model of TNF-α-induced lethal shock when administered at doses of 3, 10, and 50 mg/kg.

## Reference

1. P.A., H., Berger, S.B., Jeong, J.U., *et al.* Discovery of a first-in-class receptor interacting protein 1 (RIP1) kinase specific clinical candidate (GSK2982772) for the treatment of inflammatory diseases. *J. Med. Chem.* **60**(4), 1247-1261 (2017).

### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/31/2022

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
[WWW.CAYMANCHEM.COM](http://WWW.CAYMANCHEM.COM)